Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4091K | ISIN: US6294442099 | Ticker-Symbol: B1Q
München
20.05.24
08:02 Uhr
3,300 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NRX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
NRX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,6803,80020.05.
0,0000,00020.05.

Aktuelle News zur NRX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoNRX Pharmaceuticals, Inc. - 8-K, Current Report2
MiEarnings call: NRx Pharmaceuticals outlines strategic growth and clinical advances4
14.05.NRX Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
14.05.NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update3262024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional investor...
► Artikel lesen
10.05.NRX Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview6
08.05.NRx Pharmaceuticals eyes first commercial revenue in 2024, announces breakthroughs in bi-annual milestone update5
06.05.NRx Pharmaceuticals Plans To Seek Accelerated Approval Of NRX-10111
06.05.NRx Pharmaceuticals climbs on positive results from its bipolar depression treatment trial7
06.05.CRVS, CTMX and NRXP are among premarket gainers13
06.05.NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression104Both drugs demonstrated> 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size.37...
► Artikel lesen
01.05.CYCC, CETX and NRXP among pre-market losers10
30.04.NRX Pharmaceuticals, Inc. - 8-K, Current Report6
30.04.Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study10
30.04.NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression84NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative...
► Artikel lesen
29.04.NRX Pharmaceuticals, Inc. - 10-K/A, Annual Report5
18.04.Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?11
18.04.NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement101The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter Four upcoming milestones expected: data from trials in Suicidal...
► Artikel lesen
17.04.NRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal Flora5
17.04.NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections72New data demonstrates no impact of NRX-101 on gut or vaginal flora - considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections NRX-101 previously demonstrated...
► Artikel lesen
15.04.NRX Pharmaceuticals, Inc. - 8-K, Current Report5
Seite:  Weiter >>
72 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4